Oncobiologics, Inc. (NASDAQ:ONS) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus target price of $11.00 for the company, according to Zacks. Zacks has also given Oncobiologics an industry rank of 111 out of 265 based on the ratings given to related companies.
Oncobiologics (NASDAQ:ONS) opened at $1.42 on Tuesday. Oncobiologics has a 1 year low of $0.78 and a 1 year high of $3.95. The company has a debt-to-equity ratio of -0.01, a current ratio of 0.03 and a quick ratio of 0.03.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.